WST · NYSE · Health Care Supplies
Health Care Supplies company based in Exton, Pennsylvania.
In the last 90 days, no insider of West Pharmaceutical Services reported an open-market purchase and 6 open-market sales worth about $5.44M. The latest 13F reports cover the quarter ending Jun 30, 2026. Every figure links to its official SEC, House, Senate or USAspending record.
Last close, Oct 5, 2026
$376.76
Adjusted for splits and dividends
Last 12 months
+38.2%
S&P 500 +15.8% over the same dates
Market value
$26.5B
Last close × shares outstanding
Bets against the stock: 2.38M shares sold short (3.4% of shares outstanding), +8.3% vs the previous count, 4.5 days of normal trading to buy them back. FINRA, as of Sep 15, 2026.
Revenue
$872M
+13.8% vs the same quarter a year earlier
Free cash flow, last 12 months
$437M
This quarter $80.8M, a year earlier $102M
Net cash
$233M
Debt $203M, cash $436M, at Jun 30, 2026
Net income, last 12 months
$565M
Operating profit covers interest 151.2x
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Jul 23, 2026.
Insiders buying, last 90 days
None
No open-market purchases reported
Insiders selling, last 90 days
6 sales
$5.44M sold. Insiders sell for many reasons.
New federal contracts, 12 months
None
Nothing found for this company
Revenue, fiscal 2025
$3.07B
+6.3% vs the year before
Net income, fiscal 2025
$494M
As reported in the annual filing
Shares outstanding
70.4M
As of Jul 20, 2026
In fiscal 2025 the company spent $134M buying back its own shares and $61.2M on dividends. Cash actually paid, from its cash-flow statement.
Stock since the trade +3.2% · S&P 500 +2.3% · to Oct 5
West Pharmaceutical Services's Sr. VP & Chief HR Officer sold $921K of West Pharmaceutical Services shares. Nobody planned it ahead of time.
Stock since the trade +6.1% · S&P 500 +1.8% · to Oct 5
West Pharmaceutical Services's Sr. VP & Chief HR Officer sold $888K of West Pharmaceutical Services shares. Nobody planned it ahead of time.
Stock since the trade +8.8% · S&P 500 +1.4% · to Oct 5
West Pharmaceutical Services's Sr. VP & Chief HR Officer sold $863K of West Pharmaceutical Services shares. Nobody planned it ahead of time.
Stock since the trade +11.6% · S&P 500 +1.2% · to Oct 5
West Pharmaceutical Services's Sr. VP & Chief HR Officer sold $960K of West Pharmaceutical Services shares. Nobody planned it ahead of time.
Stock since the trade +11.6% · S&P 500 +1.2% · to Oct 5
West Pharmaceutical Services's Sr. VP & Chief HR Officer sold $960K of West Pharmaceutical Services shares. Nobody planned it ahead of time.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Short sale volume: 50.3% of the volume reported to FINRA over the last 20 trading days was marked short, below its 1-year average of 52.9%. FINRA daily files, to Oct 5, 2026.
Short sale volume is not short interest. It counts trades marked short, including market makers selling short to fill buy orders, so it is a share of daily trading, not a count of bets against the stock.
Last 12 months, adjusted daily closes
Adjusted close went from $268.07 on Oct 6, 2025 to $376.76 on Oct 5, 2026 (+40.5%). Disclosed trades in the last 12 months: 0 insider purchases, 8 insider sales, 0 Congress purchases, 0 Congress sales.
Vanguard Capital Management
Schedule 13G: passive · filed Apr 30, 2026 · 5.4M shares
Vanguard Portfolio Management
Schedule 13G: passive · filed Apr 29, 2026 · 4.1M shares
FMR LLC
Schedule 13G: passive · filed Aug 6, 2026 · 3.56M shares
Anyone owning more than 5% must file within days. Structured filings exist since December 2024, so older stakes that were never amended may be missing.
A securities lawsuit naming the company as a defendant was filed on May 5, 2025 in the U.S. District Court, E.D. Pennsylvania. A filing is an allegation, not a finding.
NEW ENGLAND TEAMSTERS PENSION FUND v. WEST PHARMACEUTICAL SERVICES, INC., 2:25-cv-02285Federal civil cases with nature of suit 850 (securities) filed in the last 3 years where the company is the first named defendant, from court records on CourtListener (Free Law Project). Coverage of court records is not complete, and shareholder derivative suits are not included.
7 certified in FY2026 Q3, vs 2 a year earlier. 7 positions in total, median offered wage $105K a year.
Labor condition applications for H-1B workers certified by the Department of Labor, counted by decision date (FY2026 Q3: Apr 1, 2026 to Jun 30, 2026, the latest quarter published). A certified application is a step before a visa petition, not a hire or a visa, and one application can cover several positions. Matched by employer ID number or name.
Top officer leaving
“Green, President, Chief Executive Officer and Chair of the Board of Directors (the “Board”) of the Company, informed the Board on March 6, 2026 of his intent to retire from those positions once his successor has been hired in order to ensure a smooth transition.”
2 insiders sold ~$1.13M in the 60 days before
8-K on sec.govTop officer leaving
“Green, President, Chief Executive Officer and Chair of the Board of Directors (the “Board) of the Company, informed the Board on March 6, 2026 of his intent to retire from those positions once his successor has been hired in order to ensure a smooth transition.”
8-K on sec.govFrom the company's 8-K, 10-K and 10-Q filings over the last two years. A flag is a reason to read the filing, not a verdict: many departures are planned retirements and many listing notices are resolved. Insider sales are shown for timing only; they are separate filings.
